AU2008283357B2 — Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof
Assigned to Shionogi and Co Ltd · Expires 2011-08-11 · 15y expired
What this patent protects
Disclosed is an optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity. Also disclosed is a pharmaceutical composition containing such a compound as an active ingredient, which makes an orally administrable platelet production control agent…
USPTO Abstract
Disclosed is an optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity. Also disclosed is a pharmaceutical composition containing such a compound as an active ingredient, which makes an orally administrable platelet production control agent. Specifically disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (In the formula, R represents a halogen atom or a C-C alkyloxy group; R represents a C-C alkyl group; R represents a C-C alkyl group; R and R independently represent a fluorine atom or a chlorine atom; R represents a C-C alkyl group or a C-C alkyloxy group; and * represents an asymmetric carbon atom.)
Drugs covered by this patent
- Mulpleta (LUSUTROMBOPAG) · Vancocin Italia
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.